Interleukin 12: still a promising candidate for tumor immunotherapy?
- Witold LasekAffiliated withDepartment of Immunology, Centre of Biostructure Research, Medical University of Warsaw Email author
- , Radosław ZagożdżonAffiliated withDepartment of Immunology, Centre of Biostructure Research, Medical University of Warsaw
- , Marek JakobisiakAffiliated withDepartment of Immunology, Centre of Biostructure Research, Medical University of Warsaw
Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.
KeywordsInterleukin 12 Cancer immunotherapy Gene therapy Cytokine
- Interleukin 12: still a promising candidate for tumor immunotherapy?
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Cancer Immunology, Immunotherapy
Volume 63, Issue 5 , pp 419-435
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Interleukin 12
- Cancer immunotherapy
- Gene therapy
- Industry Sectors